Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reclast zoledronic acid: Phase III data

In the double-blind, international Phase III Recurrent Fracture Trial in 2,127 patients ages 50-98

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE